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ABSTRACT
OBJECTIVE
To evaluate sodium-glucose cotransporter-2 (SGLT-
2) inhibitors and glucagon-like peptide-1 (GLP-1) 
receptor agonists in patients with type 2 diabetes at 




Medline, Embase, and Cochrane CENTRAL up to 11 
August 2020.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES
Randomised controlled trials comparing SGLT-2 
inhibitors or GLP-1 receptor agonists with placebo, 
standard care, or other glucose lowering treatment in 
adults with type 2 diabetes with follow up of 24 weeks 
or longer. Studies were screened independently 
by two reviewers for eligibility, extracted data, and 
assessed risk of bias.
MAIN OUTCOME MEASURES
Frequentist random effects network meta-analysis was 
carried out and GRADE (grading of recommendations 
assessment, development, and evaluation) used 
to assess evidence certainty. Results included 
estimated absolute effects of treatment per 1000 
patients treated for five years for patients at very low 
risk (no cardiovascular risk factors), low risk (three 
or more cardiovascular risk factors), moderate risk 
(cardiovascular disease), high risk (chronic kidney 
disease), and very high risk (cardiovascular disease 
and kidney disease). A guideline panel provided 
oversight of the systematic review.
RESULTS
764 trials including 421 346 patients proved 
eligible. All results refer to the addition of SGLT-2 
inhibitors and GLP-1 receptor agonists to existing 
diabetes treatment. Both classes of drugs lowered 
all cause mortality, cardiovascular mortality, non-
fatal myocardial infarction, and kidney failure 
(high certainty evidence). Notable differences were 
found between the two agents: SGLT-2 inhibitors 
reduced mortality and admission to hospital for 
heart failure more than GLP-1 receptor agonists, and 
GLP-1 receptor agonists reduced non-fatal stroke 
more than SGLT-2 inhibitors (which appeared to 
have no effect). SGLT-2 inhibitors caused genital 
infection (high certainty), whereas GLP-1 receptor 
agonists might cause severe gastrointestinal events 
(low certainty). Low certainty evidence suggested 
that SGLT-2 inhibitors and GLP-1 receptor agonists 
might lower body weight. Little or no evidence was 
found for the effect of SGLT-2 inhibitors or GLP-1 
receptor agonists on limb amputation, blindness, 
eye disease, neuropathic pain, or health related 
quality of life. The absolute benefits of these drugs 
vary substantially across patients from low to very 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Although trial results conflict, sodium-glucose transporter 2 (SGLT-2) inhibitors 
and glucagon-like peptide-1 (GLP-1) receptor agonists probably reduce 
cardiovascular and kidney disease when added to other glucose lowering 
treatment in adults with type 2 diabetes
Uncertainty remains about the relative and absolute benefits and harms of these 
drugs across all important outcomes in patients with type 2 diabetes at varying 
levels of cardiovascular and kidney disease risk
WHAT THIS STUDY ADDS 
Benefits shared by SGLT-2 inhibitors and GLP-1 receptor agonists include 
reductions in all cause and cardiovascular mortality, myocardial infarction, 
kidney failure, and serious hyperglycaemia (high certainty evidence) and lower 
body weight (low certainty) without incurring severe hypoglycaemia (high 
certainty)
The two drug classes appear to have similar relative effects on cardiovascular 
mortality, myocardial infarction, kidney failure, health related quality of life, and 
serious hyperglycaemia
Absolute benefits of these drugs vary substantially based on cardiovascular 
and renal disease risk profiles of patients with type 2 diabetes, as reflected in 
risk stratified BMJ Rapid Recommendations directly informed by this systematic 
review
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high risk of cardiovascular and renal outcomes (eg, 
SGLT-2 inhibitors resulted in 5 to 48 fewer deaths in 
1000 patients over five years; see interactive decision 
support tool (https://magicevidence.org/match-
it/200820dist/#!/) for all outcomes.
CONCLUSIONS
In patients with type 2 diabetes, SGLT-2 inhibitors 
and GLP-1 receptor agonists reduced cardiovascular 
and renal outcomes, with notable differences in 
benefits and harms. Absolute benefits are determined 
by individual risk profiles of patients, with clear 
implications for clinical practice, as reflected in the 





Diabetes affects half a billion people worldwide 
and accounted for 1.5 million deaths in 2016.1 
Glucose lowering is a mainstay of treatment.2 In 
people with type 2 diabetes and higher risks of 
cardiovascular disease, several large scale randomised 
controlled trials have investigated sodium-glucose 
cotransporter-2 (SGLT-2) inhibitors and glucagon-
like peptide-1 (GLP-1) receptor agonists and reported 
reductions in cardiovascular mortality and non-fatal 
cardiovascular complications with both classes of 
drug.3 4 The mortality reductions have not, however, 
proved consistent across trials, leaving clinicians and 
patients uncertain of the magnitude of benefits.5-8
Recommendations released in 2019 by the American 
Diabetes Association include using SGLT-2 inhibitors 
and GLP-1 receptor agonists in the management of 
diabetes for people with cardiovascular disease or 
kidney disease who have not reached their glycaemic 
target goals.2 European Society of Cardiology 
guidelines in 2019 recommended SGLT-2 inhibitors 
and GLP-1 receptor agonists in people with type 2 
diabetes and cardiovascular disease or a high risk of 
cardiovascular disease.9 National Institute for Health 
and Care Excellence (NICE) guidance, updated in 2019, 
suggested a stepped approach to intensification of 
treatment with diabetes drugs, considering metformin 
as the first treatment with additions of dual and triple 
treatment from several drug classes, including SGLT-2 
inhibitors.10
Several published systematic reviews and meta-
analyses have summarised glucose lowering 
treatments for people with type 2 diabetes, including 
a network meta-analysis of stepped intensification 
of treatment added to metformin and sulfonylurea.11 
Results from more recent meta-analyses report 
reductions in mortality and selected cardiovascular 
and renal events with both SGLT-2 inhibitors and 
GLP-1 receptor agonists.12-15 A network meta-analysis 
including all available glucose lowering treatments, 
the full range of important outcomes, GRADE (grading 
of recommendations assessment, development, 
and evaluation) certainty ratings, and estimates 
of absolute benefits and harms in patients with 
varying risks of cardiovascular and kidney disease 
remains unavailable. Moreover, several large scale 
trials published recently require updated evidence 
synthesis.5 7 8 16
We therefore conducted a systematic review and 
network meta-analysis evaluating the benefits and 
harms of SGLT-2 inhibitors and GLP-1 receptor 
agonists in adults with type 2 diabetes. This review is 
conducted as part of the BMJ Rapid Recommendations 
project, a collaborative initiative from the MAGIC 
(Making GRADE the Irresistible Choice) Evidence 
Ecosystem Foundation (https://magicevidence.org/) 
and The BMJ. The aim of the initiative is to provide 
trustworthy practice guidelines within months of 
newly released evidence, underpinned by rigorous 
evidence summaries. This systematic review is part of 
a forthcoming BMJ Rapid Recommendations cluster 
and a fuller version on MAGICapp (www.magicapp.
org). Although the network meta-analysis includes all 
classes of diabetes drugs, it focuses on these SGLT-2 
inhibitors and GLP-1 receptor agonists added to other 
diabetes drugs, and in relation to one another.17
Methods
Protocol registration
We registered the protocol for this systematic review 
with PROSPERO (CRD42019153180).
Guideline panel involvement
In accordance with the BMJ Rapid Recommendations 
process, a guideline panel that comprised content 
experts, diabetologists, nephrologists, internal 
medicine physicians, primary care physicians, 
methodologists, and patients provided critical 
oversight of the review. The panel reviewed the 
protocol, identified the population, selected and 
ranked important patient outcomes, and recommended 
baseline risks on which absolute treatment effects were 
calculated.
Search strategy
The literature search designed by an information 
specialist was conducted in Medline, Embase, and the 
Cochrane Central Register of Controlled Trials from 
March 2016 to 11 August 2020 without language 
restriction (appendix 1). The search from a previous 
network meta-analysis provided records from database 
inception to March 2016.11
Study selection
Two reviewers, working independently, screened 
citations and evaluated full text records for eligible 
studies using Covidence systematic review software 
(Veritas Health Innovation, Melbourne, VIC, Australia; 
https://www.covidence.org). A third reviewer (BT or 
SCP) resolved disagreements by consensus.
Parallel group randomised controlled trials were 
eligible if they compared SGLT-2 inhibitors or GLP-
1 receptor agonists with one another or with other 
glucose lowering treatments, placebo, or standard 
care in adults with type 2 diabetes. We included 
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studies reporting outcomes at 24 weeks or longer. 
Treatment was given either as monotherapy or added 
to non-randomised background glucose lowering 
management and other treatments.
Using definitions of outcomes specified in individual 
randomised controlled trials, the review examined all 
patient-important outcomes as defined by the guideline 
panel, regardless of whether evidence was available in 
the eligible trials: all cause mortality, cardiovascular 
mortality, non-fatal myocardial infarction, non-
fatal stroke, kidney failure, admission to hospital for 
heart failure, severe hypoglycaemia, blindness, eye 
disease requiring intervention, health related quality 
of life, body weight, amputation, neuropathic pain, 
diabetic ketoacidosis, serious hyperglycaemia, genital 
infection, Fournier gangrene, severe gastrointestinal 
events, pancreatic cancer, and pancreatitis. Glycated 
haemoglobin A1c was not identified as an outcome 
important to patients by the guideline panel, although 
it was included in the review because it is prioritised by 
some decision makers.
Data extraction
For each eligible study, two reviewers independently 
extracted the following: study characteristics (year 
of publication, country or countries, funding, 
duration), population (setting, sample size, patient 
demographics, coexisting illnesses), description of 
interventions (drug class, name, dose), and outcomes. 
Reviewers resolved disagreements by discussion or, if 
necessary, consultation with a third reviewer.
Risk of bias assessment
Two reviewers independently assessed risk of bias, 
with adjudication by a third reviewer (SCP) using the 
Cochrane tool for assessing risk of bias in randomised 
trials, which includes random sequence generation, 
allocation concealment, blinding, missing outcome 
data, and selective reporting of outcomes.18 Each 
domain was judged as low, unclear, or high risk of bias. 
Reviewers considered allocation concealment as low 
risk if there were no reported methods for allocation 
concealment and participants and investigators were 
blind to treatment allocation.
Data synthesis and analysis
For each direct comparison of two treatments, we 
conducted a frequentist pairwise meta-analysis 
using a restricted maximum likelihood estimation 
and reported, with corresponding 95% confidence 
intervals, odds ratios for dichotomous outcomes, 
mean differences for continuous outcomes (body 
weight and glycated haemoglobin A1c), and 
standardised mean difference for health related 
quality of life.19 We assessed statistical heterogeneity 
using the I2 statistic and funnel plots for evidence of 
small study effects in analyses including 10 or more 
studies.
We conducted network meta-analysis using 
frequentist methods with restricted maximum 
likelihood estimation to quantify network 
heterogeneity, assuming a common heterogeneity 
estimate within a network. We assessed agreement 
between direct and indirect estimates in every closed 
loop of evidence using node splitting approaches, and 
for the entire network using a design-by-treatment 
interaction model.20 We imputed missing standard 
deviations for continuous variables when absent 
using standard deviations borrowed from other similar 
randomised controlled trials.21 22
The guideline panel recommended five baseline risk 
categories to estimate absolute effects of treatment 
on cardiovascular and kidney outcomes in different 
categories of patients, reflecting typical clinical 
scenarios in practice. Patient categories were defined 
as very low risk (no or few (<3) cardiovascular risk 
factors), low risk (three or more cardiovascular risk 
factors), moderate risk (cardiovascular disease), high 
risk (chronic kidney disease (estimated glomerular 
filtration rate 45-75 mL/min per 1.73 m2 with 
albuminuria >300 mg/g (30 mg/mmol) or estimated 
glomerular filtration rate 15-45 mL/min per 1.73 
m2)), and very high risk (cardiovascular disease 
and chronic kidney disease)). The panel calculated 
absolute treatment effects of the network estimates 
based on the event rates from the best sources of 
evidence, including cohort studies, risk prediction 
equations, or the placebo arm in available trials.23-28 
We estimated baseline absolute risk per 1000 patients 
treated for five years, extrapolating from shorter 
term data when necessary and assuming a constant 
annual risk of the selected outcome for each year 
up to five years. A single estimate was obtained for 
all outcomes and treatment comparisons, which was 
used in combination with the baseline risk estimates 
to present results as absolute effects. We planned 
subgroup analysis if sufficient data were available 
according to trial duration, BMI, presence of high 
cardiovascular risk, and presence of chronic kidney 
disease. All pairwise and network meta-analyses 
were performed with Stata 13 MP (StataCorp, College 
Station, TX) using published routines.29
Assessment of evidence certainty
The GRADE approach provided the methods to 
assess the certainty of the evidence for direct and 
network comparisons, using a non-contextualised 
approach.30  31 Ratings of evidence certainty for 
direct estimates included considerations of risk of 
bias, inconsistency, indirectness, imprecision, and 
publication bias.
The lower of the ratings from the two direct estimates 
forming the dominant first order loop provided 
the starting point for certainty ratings for each 
indirect estimate, with further downward rating for 
intransitivity,32 if present. The estimate that provided the 
most information—direct or indirect—was the basis for 
the certainty of the network estimates. If these estimates 
contributed similar amounts of information, we chose 
the higher of the two certainty judgments. If evidence 
of incoherence between direct and indirect estimates 
existed, the certainty of the network estimate was 
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rated down, and we used the estimate with the highest 
certainty—direct or indirect—as the best estimate of the 
treatment effect. MAGICapp (https://www.magicapp.
org/) provided the platform to develop tables of the 
GRADE summary of findings. We also provide the 
absolute estimates of effect and associated uncertainties 
across risk groups, derived from best relative estimates 
of effect from the network meta-analysis. These results 
are presented in evidence summaries and decision 
aids developed in MAGICapp, including an interactive 
decision support tool for multiple treatment choices 
(https://magicevidence.org/match-it/200820dist/#!/).
Patient and public involvement
Four patient partners living with type 2 diabetes were 
included in the guideline panel that oversaw the 
generation of this paper. Patient partners were recruited 
from patient advocacy organisations and Cochrane Task 
Exchange. They were involved as full panel members in 
modifying the research question and identifying and 
prioritising patient-important outcomes. There was no 
public participation in this project.
Results
Description of included studies
The electronic search yielded 23 185 unique records. 
Screening and full text article analysis identified 764 trials 
including 421 346 patients (fig 1, appendix 2) comparing 
11 glucose lowering drugs, placebo, or standard care. 
Figure 2 shows the network of treatment comparisons in 
available trials. The trial sample size ranged from 16 to 
17 160. The median trial mean age was 57.1 years, and 
the median proportion of men was 55.6%. At baseline, 
the median trial mean glycated haemoglobin A1c was 
8.1% and BMI was 30.1. Eligibility criteria included 
coronary artery disease or macrovascular disease in 35 
trials,3 6 7 33-64 atrial fibrillation in 1 trial,65 heart failure in 
9 trials,66-74 chronic kidney disease and/or albuminuria in 
37 trials,8 75-110 and high risk of cardiovascular or kidney 
disease in 10 trials.4 5 16 111-117 Treatment with SGLT-2 
inhibitors or GLP-1 receptor agonists was generally added 
to background glucose lowering treatment.
Risk of bias
Appendix 3 presents the risk of bias in each trial. The 
key limitation was low levels of reported blinding for 
participants, investigators, and outcome assessors. Three 
hundred and seven (40.2%) of 764 trials were at low risk 
of bias in random sequence generation and 529 (69.2%) 
were at low risk of bias in allocation concealment. Four 
hundred and sixty two trials (60.5%) reported blinding 
for participants and investigators, and 105 trials (13.7%) 
reported blinding for outcome assessment. Three hundred 
and twenty eight trials (42.9%) were adjudicated as being 
at low risk of attrition bias and 355 trials (46.5%) were at 
low risk of bias from selective outcome reporting.
Outcomes
Appendix 4 presents the network plot for each 
outcome. No evidence of global network inconsistency 
or heterogeneity was found except for health related 
quality of life (appendix 5), and no serious concerns 
of incoherence between direct and indirect evidence 
(appendix 6). Appendix 7 presents network estimates 
for each drug comparison for all outcomes. The expected 
absolute differences in treatment with SGLT-2 inhibitors 
or GLP-1 receptor agonists compared with placebo and 
each other are shown in table 1, table 2, table 3, table 
4, and appendix 8. The interactive decision support tool 
at https://magicevidence.org/match-it/200820dist/#!/ 
shows absolute estimates of effect for key outcomes in 
patients with type 2 diabetes, from very low to very high 
risk of cardiovascular and renal outcomes.
All cause and cardiovascular mortality
Two hundred and thirty eight trials including 290 662 
patients reported all cause mortality. SGLT-2 inhibitors 
lowered all cause mortality compared with placebo (odds 
ratio 0.77 (95% confidence interval 0.71 to 0.83); 5 fewer 
per 1000 in five years for very low risk patients (moderate 
certainty); 15 fewer for low risk patients (high certainty); 
25 fewer for moderate risk patients (high certainty); 34 
fewer for high risk patients (high certainty); and 48 fewer 
for very high risk patients (high certainty); table 4). GLP-1 
receptor agonists lowered all cause mortality compared 
with placebo (0.88 (0.83 to 0.94); 2, 8, 13, 17, and 24 
fewer per 1000 in five years for very low, low, moderate, 
high, and very high risk patients respectively, moderate to 
high certainty; table 4).
SGLT-2 inhibitors reduced all cause mortality 
compared with GLP-1 receptor agonists (0.88 (0.79 to 
0.97); 2, 7, 12, 16, and 23 fewer per 1000 in five years for 
Full text articles excluded
Incorrect patient population
Incorrect study design
Incorrect intervention or comparator
Secondary publication of included trial
Retracted or terminated
Ongoing trial without reported data









Records screened on title and abstract
Randomised controlled trials included in review
Records identified through database searching
23 185
18 318




Records excluded during screening
764
15 993
Fig 1 | PRISMA flow diagram of studies included in the review of glucose lowering 
treatments for type 2 diabetes
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very low, low, moderate, high, and very high risk patients 
respectively, moderate to high certainty; table 3).
One hundred and thirty five trials including 
226 701 patients reported cardiovascular mortality. 
SGLT-2 inhibitors lowered cardiovascular mortality 
compared with placebo (0.84 (0.76 to 0.92); 2, 7, 
12, 16, and 24 fewer per 1000 in five years for very 
low, low, moderate, high, and very high risk patients 
respectively, moderate to high certainty; table 1), as 



























Fig 2 | Network plot of trials evaluating glucose lowering treatments for type 2 diabetes. Network shows the number 
of participants assigned to each glucose lowering class with the size of each circle proportional to the number of 
randomly assigned participants in the treatment comparisons (sample size for the specific treatment shown in 
brackets). Line widths are proportional to the number of trials comparing the corresponding pair of treatments. 
The most frequent drug comparison was DPP-4 inhibitors compared with placebo. DPP-4=dipeptidyl peptidase-4 
inhibitors; GLP-1=glucagon-like peptide-1; SGLP-1=sodium-glucose cotransporter-2
Table 1 | Summary of anticipated absolute differences comparing sodium-glucose cotransporter-2 inhibitor treatment with placebo treatment per 1000 
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Hospital 
























(1 fewer to 0) 
⊕⊕⊕
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(119 more to 
170 more) 
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1.92 kg lower 
(2.23 lower 
to 1.62 lower) 



































































































(73 fewer to 44 
fewer) 
⊕⊕⊕⊕
*Risk categories represent the following patient populations: very low=no or less than three cardiovascular risk factors; low=three or more cardiovascular risk factors; moderate=cardiovascular 
disease; high=chronic kidney disease (reduced glomerular filtration rate or macroalbuminuria); very high=cardiovascular disease and chronic kidney disease. 
Certainty of the evidence for each estimate is shown: high certainty ⊕⊕⊕⊕; moderate certainty ⊕⊕⊕; low certainty ⊕⊕; very low certainty ⊕.
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5, 9, 12, and 18 fewer per 1000 in five years for very 
low, low, moderate, high, and very high risk patients 
respectively, moderate to high certainty; table 2). SGLT-
2 inhibitors and GLP-1 receptor agonists did not have 
different effects on cardiovascular mortality (0.96 
(0.84 to 1.09, moderate to high certainty; appendix 8).
Non-fatal myocardial infarction
Two hundred and eight trials including 265 921 
patients reported non-fatal myocardial infarction. 
SGLT-2 inhibitors lowered odds of non-fatal 
myocardial infarction compared with placebo (odds 
ratio 0.87 (95% confidence interval 0.79 to 0.97); 4, 
7, 13, 14, and 21 fewer per 1000 in five years for very 
low, low, moderate, high, and very high risk patients 
respectively, moderate to high certainty; appendix 8), 
as did GLP-1 receptor agonists (0.92 (0.85 to 0.99); 
2, 4, 8, 9, 13 fewer per 1000 in five years for very 
low, low, moderate, high, and very high risk patients 
respectively, moderate to high certainty; appendix 
8). SGLT-2 inhibitors and GLP-1 receptor agonists 
did not have different effects on non-fatal myocardial 
infarction (0.95 (0.84 to 1.08); moderate to high 
certainty; appendix 8).
Non-fatal stroke
One hundred and seventy six trials including 261 434 
patients reported non-fatal stroke. SGLT-2 inhibitors 
Table 2 | Summary of anticipated absolute differences comparing glucagon-like peptide-1 receptor agonist treatment with placebo treatment per 1000 








infarction Non-fatal stroke Kidney failure
Hospital 















(4 fewer to 0) 
⊕⊕⊕
5 fewer 




(1 fewer to 0) 
⊕⊕⊕
0 
(1 fewer to 0) 
⊕⊕⊕
58 more (9 more 
to 142 more) 
⊕⊕
145 kg lower 
(1.72 lower 
to 1.18 lower) 




































































































(28 fewer to 5 
more) 
⊕⊕⊕⊕
*Risk categories represent the following patient populations: very low=no or less than three cardiovascular risk factors; low=three or more cardiovascular risk factors; moderate=cardiovascular 
disease; high=chronic kidney disease (reduced glomerular filtration rate or macroalbuminuria); very high=cardiovascular disease and chronic kidney disease. 
Certainty of the evidence for each estimate is shown: high certainty ⊕⊕⊕⊕; moderate certainty ⊕⊕⊕; low certainty ⊕⊕; very low certainty ⊕.
Table 3 | Summary of anticipated absolute differences comparing sodium-glucose cotransporter-2 inhibitor treatment with glucagon-like peptide-1 
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(1 fewer to 0) 
⊕⊕
1 fewer 
(2 fewer to 1 
fewer) 
⊕⊕⊕
0.47 kg lower 
(0.09 lower 
to 0.85 lower) 
over 6 months 
⊕⊕⊕
1 more 
(0 to 3 more) 
⊕⊕⊕
5 more 




















































































(40 fewer to 6 
fewer)
5 fewer 
(22 fewer to 12 
more)
7 fewer 
(24 fewer to 
11 more)
27 more 
(4 more to 53 
more)
10 fewer 
(34 fewer to 
20 more)
48 fewer 
(66 fewer to 
27 fewer)
*Risk categories represent the following patient populations: very low=no or less than three cardiovascular risk factors; low=three or more cardiovascular risk factors; moderate=cardiovascular 
disease; high=chronic kidney disease (reduced glomerular filtration rate or macroalbuminuria); very high=cardiovascular disease and chronic kidney disease. 
Certainty of the evidence for each estimate is shown: high certainty ⊕⊕⊕⊕; moderate certainty ⊕⊕⊕; low certainty ⊕⊕; very low certainty ⊕.
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Table 4 | GRADE summary of findings to illustrate absolute effects based on cardiovascular and renal risk, for all cause mortality for sodium-glucose 
cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists compared with placebo or each other
Comparison
Relative effect (odds 
ratio (95% CI))
Anticipated absolute effects over five years Anticipated absolute 




 effects (GRADE) Plain text summary
Baseline 
risk* Risk with control
Risk with 
 intervention
SGLT-2 inhibitor v 
placebo




5 fewer per 1000 
(from 3 fewer to 6 
fewer)
Moderate due to 
indirectness
SGLT-2 inhibitor treatment probably 
reduces all cause mortality in people 
with diabetes and few or no cardiovas-
cular risk factors




15 fewer per 1000 
(from 11 fewer to 19 
fewer)
High SGLT-2 inhibitor treatment reduces all 
cause mortality in people with diabe-
tes and cardiovascular risk factors




25 fewer per 1000 
(from 18 fewer to 32 
fewer)
High SGLT-2 inhibitor treatment reduces 
all cause mortality in people with 
diabetes and established cardiovascu-
lar disease




34 fewer per 1000 
(from 25 fewer to 43 
fewer)
High SGLT-2 inhibitor treatment reduces all 
cause mortality in people with diabe-
tes and chronic kidney disease




48 fewer per 1000 
(from 35 fewer to 61 
fewer)
High SGLT-2 inhibitor treatment reduces 
all cause mortality in people with dia-
betes and established cardiovascular 
disease and chronic kidney disease
GLP-1 receptor 
agonist v placebo
0.88 (0.83 to 0.94) Very low Placebo: 20 per 
1000
GLP-1 receptor 
agonist: 18 per 
1000
2 fewer per 1000 
(from 1 fewer to 3 
fewer)
Moderate due to 
indirectness
GLP-1 receptor agonist treatment 
probably reduces all cause mortality 
in people with diabetes and few or no 
cardiovascular risk factors
Low Placebo: 70 per 
1000
GLP-1 receptor 
agonist: 62 per 
1000
8 fewer per 1000 
(from 4 fewer to 11 
fewer)
High GLP-1 receptor agonist treatment 
reduces all cause mortality in people 
with diabetes and cardiovascular risk 
factors
Moderate Placebo: 120 per 
1000
GLP-1 receptor 
agonist: 107 per 
1000
13 fewer per 1000 
(from 6 fewer to 18 
fewer)
High GLP-1 receptor agonist treatment 
reduces all cause mortality in people 
with diabetes and established cardio-
vascular disease
High Placebo: 170 per 
1000
GLP-1 receptor 
agonist: 153 per 
1000
17 fewer per 1000 
(from 9 fewer to 25 
fewer)
High GLP-1 receptor agonist treatment 
reduces all cause mortality in people 
with diabetes and chronic kidney 
disease
Very high Placebo: 265 per 
1000
GLP-1 receptor 
agonist: 241 per 
1000
24 fewer per 1000 
(from 12 fewer to 35 
fewer)
High GLP-1 receptor agonist treatment 
reduces all cause mortality in people 
with diabetes and established cardi-
ovascular disease and chronic kidney 
disease
SGLT-2 inhibitor 
v GLP-1 receptor 
agonist
0.88 (0.79 to 0.98) Very low GLP-1 receptor 




2 fewer per 1000 
(from 1 fewer to 4 
fewer)
Moderate due to 
indirectness
SGLT-2 inhibitor treatment probably 
reduces all cause mortality compared 
with GLP-1 receptor agonist treatment 
in people with diabetes and few or no 
cardiovascular risk factors
Low GLP-1 receptor 




7 fewer per 1000 
(from 2 fewer to 12 
fewer)
High SGLT-2 inhibitor treatment reduces all 
cause mortality compared with GLP-1 
receptor agonist treatment in people 
with diabetes and cardiovascular risk 
factors
Moderate GLP-1 receptor 




12 fewer per 1000 
(from 3 fewer to 21 
fewer)
High SGLT-2 inhibitor treatment reduces all 
cause mortality compared with GLP-1 
receptor agonist treatment in people 
with diabetes and established cardio-
vascular disease
High GLP-1 receptor 




16 fewer per 1000 
(from 4 fewer to 28 
fewer)
High SGLT-2 inhibitor treatment reduces all 
cause mortality compared with GLP-1 
receptor agonist treatment in people 
with diabetes and chronic kidney 
disease
Very high GLP-1 receptor 




23 fewer per 1000 
(from 6 fewer to 40 
fewer)
High SGLT-2 inhibitor treatment reduces 
all-cause mortality compared with 
GLP-1 receptor agonist treatment in 
people with diabetes and established 
cardiovascular disease and chronic 
kidney disease
GRADE=grading of recommendations assessment, development, and evaluation.
*Risk categories represent the following patient populations: very low=no or less than three cardiovascular risk factors; low=three or more cardiovascular risk factors; moderate=cardiovascular 
disease; high=chronic kidney disease (reduced glomerular filtration rate or macroalbuminuria); very high=cardiovascular disease and chronic kidney disease. 
The point estimate of the absolute effect for GLP-1 receptor agonist treatment, obtained from GLP-1 receptor agonist treatment versus placebo, was used to calculate the absolute effect for SGLT-
2 inhibitors versus GLP-1 receptor agonists.
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had little or no effect on non-fatal stroke (odds ratio 
1.01 (95% confidence interval 0.89 to 1.14); moderate 
to high certainty; appendix 8). GLP-1 receptor agonists 
reduced non-fatal stroke (0.84 (0.76 to 0.93); 5, 9, 
16, 17, and 25 fewer per 1000 in five years for very 
low, low, moderate, high, and very high risk patients 
respectively, moderate to high certainty; appendix 8). 
SGLT-2 inhibitors had higher odds of non-fatal stroke 
than GLP-1 receptor agonists (1.20 (1.03 to 1.41); 
moderate to high certainty; appendix 8).
Kidney failure
Thirty three trials including 98 284 patients reported 
kidney failure, defined generally as estimated 
glomerular filtration rate below 15 ml/min per 1.73 
m2 or start of kidney replacement treatment. SGLT-
2 inhibitors reduced kidney failure (odds ratio 0.71 
(95% confidence interval 0.57 to 0.89); 1,3, 6, 25, 
and 38 fewer per 1000 in five years for very low, 
low, moderate, high, and very high risk patients 
respectively, moderate to high certainty; appendix 8). 
GLP-1 receptor agonists also reduced kidney failure 
(0.78 (0.67 to 0.92); 0, 2, 4, 19, and 29 fewer per 1000 
in five years for very low, low, moderate, high, and 
very high risk patients respectively, moderate to high 
certainty; appendix 8). SGLT-2 inhibitors and GLP-
1 receptor agonists probably did not have different 
effects on kidney failure (0.91 (0.69 to 1.20); low to 
moderate certainty).
Admission to hospital for heart failure
One hundred and forty nine trials including 242 361 
patients reported admission to hospital for heart 
failure. SGLT-2 inhibitors reduced admission for heart 
failure (odds ratio 0.70 (95% confidence interval 0.63 
to 0.77); 2, 9, 23, 29, and 58 fewer per 1000 in five 
years for very low, low, moderate, high, and very high 
risk patients respectively, moderate to high certainty; 
appendix 8). GLP-1 receptor agonists had little or no 
effect on hospitalisation for heart failure (0.94 (0.85 to 
1.03), moderate to high certainty; appendix 8). SGLT-
2 inhibitors reduced hospitalisation for heart failure 
compared with GLP-1 receptor agonists (0.74 (0.65 
to 0.85); 1, 7, 18, 24, and 48 fewer per 1000 in five 
years for very low, low, moderate, high, and very high 
risk patients respectively, moderate to high certainty; 
table 3).
Blindness and eye disease requiring intervention
Seven trials including 68 221 patients reported 
blindness. The results of the network meta-analysis 
were uninformative as blindness was rarely reported 
and the confidence intervals for estimated treatment 
effects were very wide (appendix 7). The outcome of 
eye disease requiring intervention was not specifically 
reported in any trial.
Health related quality of life
Twenty five trials including 11 912 patients reported 
health related quality of life during a median follow-
up of six months. The reported instruments included 
the Diabetes Treatment Satisfaction Questionnaire, the 
Short Form 12 and 36, the EuroQoL five dimensions (EQ-
5D), the Diabetes Quality of Life, Treatment Satisfaction 
Status Scale, and the Impact of Weight on Quality of 
Life. SGLT-2 inhibitors had uncertain effects on health 
related quality of life (standardised mean difference 0.14 
(95% confidence interval −0.08 to 0.36); low certainty; 
appendix 8). GLP-1 receptor agonists might increase 
health related quality of life (0.13 (0.03 to 0.23); low 
certainty; appendix 8). No evidence was found that 
SGLT-2 inhibitors and GLP-1 receptor agonists had 
different effects on health related quality of life (0.01 
(−0.19 to 0.20); low certainty; appendix 8).
Body weight
Four hundred and sixty nine trials including 226 361 
patients reported body weight during a median follow-
up of six months. SGLT-2 inhibitor treatment and GLP-
1 receptor agonist treatment might lower body weight 
(mean difference for SGLT-2 inhibitors −1.92 kg (95% 
confidence interval −2.23 to −1.62); low certainty; 
mean difference for GLP-1 receptor agonists −1.45 kg 
(−1.72 to −1.18); low certainty; appendix 8). SGLT-2 
inhibitors appeared to lower body weight to a greater 
extent than GLP-1 receptor agonists (−0.47 kg (−0.85 
to −0.09); moderate certainty).
Glycated haemoglobin A1c
Six hundred and four trials including 242 745 patients 
reported glycated haemoglobin A1c during a median 
follow-up of six months. SGLT-2 inhibitors (mean 
difference −0.60% (95% confidence interval −0.67 
to −0.54); low certainty) and GLP-1 receptor agonists 
(−0.89% (−0.95 to −0.82); low certainty) might lower 
glycated haemoglobin A1c levels more than placebo 
(low certainty). GLP-1 receptor agonists reduced 
glycated haemoglobin A1c levels to a greater extent 
than SGLT-2 inhibitors (mean difference −0.28% (95% 
CI −0.37 to −0.19); high certainty).
Other outcomes
GLP-1 receptor agonists reduced serious 
hyperglycaemia with moderate to high certainty (15 
fewer events in 1000 patients treated with GLP-1 
receptor agonists over five years). Results showed the 
effects of treatment on amputation or neuropathic pain 
were very uncertain (appendix 8).
Harms
No difference in the odds of serious hypoglycaemia 
was found in a comparison of SGLT-2 inhibitor 
or GLP-1 receptor agonist treatment with placebo 
or with each other in high or moderate certainty 
evidence (appendix 8). SGLT-2 inhibitor treatment 
and GLP-1 receptor agonist treatment probably did 
not increase diabetic ketoacidosis compared with 
placebo or each other (moderate certainty). SGLT-2 
inhibitors increased genital infection compared with 
placebo and GLP-1 receptor agonists (high certainty). 
The effects of treatments on Fournier gangrene were 
uncertain. GLP-1 receptor agonists might incur severe 
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gastrointestinal events (low certainty). An increase 
in pancreatic cancer or pancreatitis is probably not 
likely with SGLT-2 inhibitor or GLP-1 receptor agonist 
treatment compared with placebo (low to moderate 
certainty), and there might be no difference between 
SGLT-2 inhibitor and GLP-1 receptor agonist treatment 
for pancreatic cancer (low certainty). SGLT-2 inhibitor 
treatment might incur a lower risk of pancreatitis than 
GLP-1 receptor agonist treatment (low certainty).
No evidence was found that treatment effects differed 
according to trial level characteristics, including trial 
duration, BMI, cardiovascular risk, and presence of 
chronic kidney disease (appendix 9).
Discussion
Principal findings
This network meta-analysis provides high certainty 
evidence that SGLT-2 inhibitors and GLP-1 receptor 
agonists, when added to other diabetes treatment, 
reduce mortality, non-fatal myocardial infarction, 
kidney failure, and serious hyperglycaemia. In the 
absence of head-to-head trials, we also found high 
certainty evidence for notable differences between 
SGLT-2 inhibitors and GLP-1 receptor agonists; SGLT-2 
inhibitors reduced all cause mortality and admission 
to hospital for heart failure more than GLP-1 receptor 
agonists, whereas GLP-1 receptor agonists reduced non-
fatal stroke more than SGLT-2 inhibitors (which appeared 
to have no effect). Differential effects of SGLT-2 inhibitors 
and GLP-1 receptor agonists on other patient important 
outcomes included lower body weight and increased 
quality of life, albeit with small absolute differences. 
Harms also differed. SGLT-2 inhibitors caused genital 
infection, and GLP-1 receptor agonists might increase 
severe gastrointestinal events. Importantly, the absolute 
benefits for cardiovascular and renal outcomes varied 
substantially for patients, depending on their absolute 
cardiovascular risk (very low to very high; https://
magicevidence.org/match-it/200820dist/#!/) Taken 
together, the results have clear implications for clinical 
practice, as reflected in the BMJ Rapid Recommendations 
directly informed by our systematic review.
Strength and limitations of this study
The strengths of the review include a sensitive 
search to identify eligible trials, and independent 
study identification, selection, data extraction, 
and adjudication of risk of bias by two reviewers. 
The review used the GRADE approach to report the 
certainty of available evidence and reported estimated 
absolute risks for all outcomes, including patients with 
varying risks of cardiovascular and kidney disease. 
Limitations include the heterogeneity in clinical 
settings of the included trials, although the consistency 
of results across studies diminishes this concern. Some 
outcomes resulted in imprecise estimates of effects and 
low certainty evidence.
Clinical uncertainties
SGLT-2 inhibitors failed to reduce non-fatal stroke 
in the same way that it reduced other cardiovascular 
endpoints, a finding not scientifically intuitive. 
Trials generally did not include patients with lowest 
cardiovascular risk. Accordingly, the certainty of 
evidence was graded down for the lowest risk patients 
owing to indirectness. The panel agreed that a non-
contextualised approach was appropriate to assess 
imprecision in estimates of effects to inform judgments 
about the certainty of evidence in the network meta-
analysis. We therefore did not adjudicate whether the 
range of treatment effects for each outcome was trivial, 
small, moderate, or large; assess critical outcomes 
simultaneously; or make inferences about their 
value relative to each other.31 The related BMJ Rapid 
Recommendation will adjudicate the importance of 
the absolute effects of treatment and rate certainty 
accordingly. This approach might lower the adjudicated 
evidence certainty for several outcomes that inform 
the BMJ Rapid Recommendations. Whether SGLT-2 
inhibitors and GLP-1 receptor agonists given together 
provide additional benefits compared with each 
treatment alone is not answered by this review. Notably, 
the effects of treatment on glycated haemoglobin 
A1c and body weight were provided in trials with an 
average follow up of six months. Possibly, the relative 
effects of the SGLT-2 inhibitor and GLP-1 receptor 
agonist treatment on these outcomes might have been 
different in shorter duration trials than in the longer 
therapeutic evaluations of cardiovascular outcomes.
Comparisons with other studies
This systematic review included substantially more 
trials—including large and recently published trials—
and patients than previously reported reviews and is 
based on priority setting and received oversight by a 
panel with a range of clinical and lived experiences. 
SGLT-2 inhibitors and GLP-1 receptor agonists had 
similar treatment effects on mortality as observed by 
a previous network meta-analysis published in 2016, 
although precision in the treatment estimates has 
increased substantially.11 The results provide evidence 
to support guideline recommendations made in 2019 
that patients at highest risk of cardiovascular disease 
and kidney disease are likely to have important benefits 
on risks of cardiovascular events and heart failure with 
SGLT-2 inhibitors.2 9 This network meta-analysis aims 
to provide a broader representation of both relative 
and absolute estimates of a wide range of important 
clinical outcomes.
The analysis is consistent with large scale 
observational analyses of SGLT-2 inhibitor treatment 
in a range of countries and settings, which suggest 
beneficial effects on a range of clinical outcomes, 
including reduced mortality and heart failure in people 
with diabetes at low cardiovascular risk and those 
with atherosclerotic cardiovascular disease.118 119 The 
effects of treatment in the available randomised trials in 
our analyses are smaller than seen with observational 
data, as the trial data enable analyses that reduce 
the risks of confounding by treatment indication; 
in other words, in real world datasets, people who 
receive drug treatment might be healthier or have 
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other characteristics that lead to better outcomes than 
people who are not prescribed treatment. The present 
review can discern important differences between the 
effect of SGLT-2 inhibitors and GLP-1 receptor agonists 
on mortality and heart failure, not identified in large 
scale non-randomised studies.120
Policy implications
This systematic review of 764 clinical trials provides 
detailed information for decision makers about the 
benefits and harms of SGLT-2 inhibitors and GLP-1 
receptor agonists on important outcomes in adults with 
type 2 diabetes. It includes trials with publicly available 
information up to August 2020. A core finding suggests 
that there is high certainty that SGLT-2 inhibitors 
reduce all cause and cardiovascular mortality, non-
fatal myocardial infarction, kidney failure, and 
admission to hospital for heart failure. GLP-1 receptor 
agonist treatment reduces all cause and cardiovascular 
mortality, non-fatal myocardial infarction, non-fatal 
stroke, and kidney failure. SGLT-2 inhibitor treatment 
reduces all cause mortality and admission to hospital 
for heart failure to a greater extent than GLP-1 receptor 
agonist treatment, whereas GLP-1 receptor agonist 
treatment reduces non-fatal stroke more than SGLT-2 
inhibitors. The effect of SGLT-2 inhibitors and GLP-
1 receptor agonists on many other important patient 
outcomes is uncertain. Glycated haemoglobin A1c 
was not chosen as an important outcome in the review 
by the oversight panel, which included patients and 
clinicians, but it was reported as it is considered by 
some decision makers to be a measure of glycaemic 
control and indicative of a more immediate measure of 
diabetes control.
Conclusions
Trials of SGLT-2 inhibitors in people with existing 
cardiovascular disease and chronic kidney disease with 
or without diabetes are emerging or ongoing,7  6  9  121 
indicating that SGLT-2 treatment decreases heart 
failure in the absence of type 2 diabetes. The findings of 
the Dapagliflozin and Prevention of Adverse outcomes 
in Chronic Kidney Disease (DAPA-CKD) randomised 
controlled trial are awaited to identify whether 
dapagliflozin decreases kidney and cardiovascular 
events in people regardless of the presence of 
diabetes.121
In conclusion, this network meta-analysis provides 
evidence of the absolute benefits and harms of SGLT-
2 inhibitors and GLP-1 receptor agonists. The balance 
of benefits and harms depends on individual risk 
profiles of patients, and thus the results support 
a risk stratified approach for provision of SGLT-2 
inhibitors and GLP-1 receptor agonists to patients 
with type 2 diabetes. Accordingly, the associated BMJ 
Rapid Recommendations will provide risk stratified 
recommendations and highlight the need for shared 
decision making to allow patients and clinicians to 
make well informed decisions together.
These data provide direct evidence for the absolute 
benefits and harms of SGLT-2 inhibitors and GLP-1 
receptor agonists. The findings of this research paper 
raise questions about how they should be used in 
clinical practice. In the linked article, readers will 
find recommendations on SGLT-2 inhibitors and GLP-
1 receptor agonists based on data from this paper. To 
do this a guideline panel has considered how direct 
this evidence is and using GRADE methodology has 
integrated this with, for example, the values and 
preferences of patients and resource implications. To 
read more about the guidelines please see the guideline 
article in this package.
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